Announcement on Investment in Construction of Green Bio‑manufacturing Project by Wholly‑owned Subsidiary
Securities code: 600789 Securities abbreviation: Lukang Pharmaceutical Announcement number: 2026-035
Shandong Lukang Pharmaceutical Co., Ltd.
Regarding the investment and construction of green biomanufacturing projects by wholly-owned subsidiaries
announcement
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
Name of investment target: Green biomanufacturing project
Investment amount: 370.1243 million yuan
Approval and other related procedures that need to be performed before the transaction is implemented
This investment has been reviewed and approved by the 15th (temporary) meeting of the 11th board of directors of Shandong Lukang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") on August 5, 2026. This project is within the approval authority of the company's board of directors and does not need to be submitted to the company's shareholders' meeting for review.
Other risk matters that investors need to pay attention to
This project is a judgment made by the company based on the current market situation and industry prospects, and comprehensive consideration of the company's existing business and strategic development. Subsequently, it may be affected by various risk factors such as macroeconomics, industry competition, changes in market demand, policy uncertainty, and operational management, and investment returns are uncertain.
1. Investment Overview
(1) Overview of this investment
- Overview of this investment
In order to accelerate the development of the bio-manufacturing sector and accelerate the implementation of synthetic biological products, the company plans to invest 370.1243 million yuan in the construction of green bio-manufacturing projects.
- Transaction elements of this transaction
□Newly established company
□Capital increase in existing company (□Same proportion □Not the same proportion)--Type of company before capital increase: □Wholly owned subsidiary □Holding subsidiary investment type
□A company with a shareholding □A company without a shareholding
☑Invest in new projects
□Others: _________
Investment target name Green biomanufacturing project
☑ Confirmed, specific amount (10,000 yuan): 37,012.43 investment amount
□ Not yet determined
☑Cash
☑Own funds
□Raise funds
□Bank loan
Investment method
☑Others: self-raised funds
□Physical assets or intangible assets
□Equity
□Others:______
Is it cross-border □Yes ☑No
(2) The deliberation status of the board of directors and whether it needs to be reviewed and approved by the shareholders’ meeting and approved by relevant departments.
The company held the 15th (temporary) meeting of the 11th board of directors on August 5, 2026, and reviewed and approved the "Proposal on Investment and Construction of Continuous Intelligent Manufacturing of Chemical API Projects" with 9 votes in favor, 0 votes against, and 0 abstentions. This project is within the approval authority of the company's board of directors and does not need to be submitted to the company's shareholders' meeting for review.
(3) Clearly state whether it is a related transaction or a major asset reorganization matter.
According to the "Shanghai Stock Exchange Stock Listing Rules", "Shanghai Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 5 - Transactions and Related Transactions" and other relevant regulations, this transaction does not constitute a related transaction, nor does it constitute a major asset reorganization as stipulated in the "Administrative Measures for Major Asset Reorganization of Listed Companies".
2. Basic situation of investment projects
(1) Overview of investment projects
In order to accelerate the development of the bio-manufacturing sector and accelerate the implementation of synthetic biological products, the company plans to invest 370.1243 million yuan in the construction of green bio-manufacturing projects. The project will build new Class A factory buildings, Class C factory buildings, Class C warehouses, elevated warehouses, control rooms, liquid tank areas, comprehensive buildings, etc.
(2) Detailed information on investment projects
- Basic situation of the project
Investment type ☑Invest in new projects
Project Name Green Biomanufacturing Project
The project will build new Class A factory buildings, Class C factory buildings, Class C warehouses, and elevated project main contents
Warehouse, control room, liquid tank area, comprehensive building, etc.
Construction site: No. 88, Hualu Road, Taiping Town, Zoucheng City, Jining City, Shandong Province
Total project investment amount (10,000 yuan) 37,012.43
Amount of investment in listed companies (10,000
37,012.43
Yuan)
Project construction period (months) Estimated 18 months (subject to actual completion date)
Whether it belongs to the main business scope ☑Yes □No
- Capital contributions from major investors
The company's wholly-owned subsidiary Shandong Lukang Biomanufacturing Co., Ltd. (hereinafter referred to as the "Biomanufacturing Company") is the construction subject of this project and plans to invest 370.1243 million yuan in the construction of this project.
- Current progress of the project
The company's planned investment and construction project has completed the preliminary feasibility study. Subsequently, it will carry out the "three simultaneous" formalities of project establishment, safety assessment, environmental assessment and energy assessment, etc., and will be gradually implemented according to the government's approval and filing status and the construction plan.
- Project market positioning and feasibility analysis
Biomanufacturing is one of the company's key development directions. With the development of genetic engineering technology, the boundaries of fermentation applications continue to expand, and the company's products extend from pharmaceutical intermediates and raw materials to natural products, bio-based new materials and other fields. The implementation of this project will expand the production capacity of biomanufacturing products and accelerate the development of the biomanufacturing sector.
(3) Investment methods and related circumstances
The sources of funds for the proposed investment and construction project include but are not limited to self-owned and self-raised funds or other methods that comply with laws and regulations. They do not involve the company's fundraising. The company will make reasonable plans and adjustments to the project implementation progress based on the actual situation.
3. The impact of this investment on listed companies
The project plans to build a dedicated production line for synthetic biological products with "leading technology and international standards", which will promote the transformation of the company's product structure and drive the optimization of industrial structure and high-quality development with technological innovation.
4. Risk warning
This project is a judgment made by the company based on the current market situation and industry prospects, and comprehensive consideration of the company's existing business and strategic development. Subsequently, it may be affected by various risk factors such as macroeconomics, industry competition, changes in market demand, policy uncertainty, and operational management, and investment returns are uncertain.
Announcement is hereby made.
Board of Directors of Shandong Lukang Pharmaceutical Co., Ltd.
August 6, 2026